Aptahem AB

Aptahem Secures Chinese Patent Protection for RNA-Based Anti-Inflammatory Therapy Through 2038

- Aptahem AB received Notice of Allowance in China for patent application covering nucleic acid molecules with anti-inflammatory, anti-coagulant, and organ-protective properties. - The granted patent will provide intellectual property protection until 2038 for the company's RNA-based pharmaceutical technology platform. - CEO Mikael Lindstam emphasized that Chinese patent protection strengthens Aptahem's global position and attractiveness to potential partners in one of the world's largest pharmaceutical markets. - The company's lead candidate Apta-1 is currently in early clinical phase development for treating sepsis and related critical conditions.